TW202221125A - 用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法 - Google Patents
用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法 Download PDFInfo
- Publication number
- TW202221125A TW202221125A TW110127422A TW110127422A TW202221125A TW 202221125 A TW202221125 A TW 202221125A TW 110127422 A TW110127422 A TW 110127422A TW 110127422 A TW110127422 A TW 110127422A TW 202221125 A TW202221125 A TW 202221125A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- amino acid
- nucleotide sequence
- sequence
- acid sequence
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 19
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 title claims 64
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000007812 deficiency Effects 0.000 title abstract 2
- 101000997662 Homo sapiens Lysosomal acid glucosylceramidase Proteins 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 230000003612 virological effect Effects 0.000 claims abstract 48
- 239000002245 particle Substances 0.000 claims abstract 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract 17
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 230000002708 enhancing effect Effects 0.000 claims abstract 5
- 101150028412 GBA gene Proteins 0.000 claims abstract 4
- 230000003247 decreasing effect Effects 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 186
- 125000003729 nucleotide group Chemical group 0.000 claims 153
- 239000002773 nucleotide Substances 0.000 claims 147
- 230000004048 modification Effects 0.000 claims 80
- 238000012986 modification Methods 0.000 claims 80
- 108010017544 Glucosylceramidase Proteins 0.000 claims 62
- 108020004707 nucleic acids Proteins 0.000 claims 38
- 102000039446 nucleic acids Human genes 0.000 claims 38
- 150000007523 nucleic acids Chemical class 0.000 claims 38
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 32
- 238000006467 substitution reaction Methods 0.000 claims 23
- 210000004027 cell Anatomy 0.000 claims 21
- 108090000565 Capsid Proteins Proteins 0.000 claims 16
- 102100023321 Ceruloplasmin Human genes 0.000 claims 16
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 15
- 108091029500 miR-183 stem-loop Proteins 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 210000001519 tissue Anatomy 0.000 claims 14
- 108091070501 miRNA Proteins 0.000 claims 11
- 125000006850 spacer group Chemical group 0.000 claims 11
- 208000015872 Gaucher disease Diseases 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 102000004961 Furin Human genes 0.000 claims 8
- 108090001126 Furin Proteins 0.000 claims 8
- 238000003776 cleavage reaction Methods 0.000 claims 8
- 230000007017 scission Effects 0.000 claims 8
- 230000009261 transgenic effect Effects 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000003623 enhancer Substances 0.000 claims 7
- 238000001990 intravenous administration Methods 0.000 claims 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims 7
- 208000018360 neuromuscular disease Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 239000002777 nucleoside Substances 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000000626 neurodegenerative effect Effects 0.000 claims 4
- 230000002981 neuropathic effect Effects 0.000 claims 4
- 108050007079 Saposin Proteins 0.000 claims 3
- 102000017852 Saposin Human genes 0.000 claims 3
- 210000000133 brain stem Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 210000001103 thalamus Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 claims 2
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 claims 2
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 claims 2
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 claims 2
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 claims 2
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 claims 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 108010000720 Excitatory Amino Acid Transporter 2 Proteins 0.000 claims 2
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 claims 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 claims 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 2
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims 2
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims 2
- 108091007780 MiR-122 Proteins 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 102100023057 Neurofilament light polypeptide Human genes 0.000 claims 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 2
- 102100038931 Proenkephalin-A Human genes 0.000 claims 2
- 102100036197 Prosaposin Human genes 0.000 claims 2
- 101710152403 Prosaposin Proteins 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 108010056354 Ubiquitin C Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000001638 cerebellum Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims 2
- 230000002132 lysosomal effect Effects 0.000 claims 2
- 108091051828 miR-122 stem-loop Proteins 0.000 claims 2
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims 2
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000001577 neostriatum Anatomy 0.000 claims 2
- 230000002232 neuromuscular Effects 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 108010074732 preproenkephalin Proteins 0.000 claims 2
- 102220080600 rs797046116 Human genes 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 1
- 102100026031 Beta-glucuronidase Human genes 0.000 claims 1
- 101150044789 Cap gene Proteins 0.000 claims 1
- 102100036912 Desmin Human genes 0.000 claims 1
- 108010044052 Desmin Proteins 0.000 claims 1
- 108010092674 Enkephalins Proteins 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 102000053187 Glucuronidase Human genes 0.000 claims 1
- 108010060309 Glucuronidase Proteins 0.000 claims 1
- 102100030651 Glutamate receptor 2 Human genes 0.000 claims 1
- 101710087631 Glutamate receptor 2 Proteins 0.000 claims 1
- 102100027377 HBS1-like protein Human genes 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims 1
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims 1
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 102000001435 Synapsin Human genes 0.000 claims 1
- 108050009621 Synapsin Proteins 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 claims 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 210000005045 desmin Anatomy 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 229960002856 eliglustat Drugs 0.000 claims 1
- FJZZPCZKBUKGGU-AUSIDOKSSA-N eliglustat Chemical compound C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 229960002127 imiglucerase Drugs 0.000 claims 1
- 108010039650 imiglucerase Proteins 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000005732 intercellular adhesion Effects 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960001512 miglustat Drugs 0.000 claims 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001144 postural effect Effects 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 101150066583 rep gene Proteins 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims 1
- 229950002652 safinamide Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 229960001832 taliglucerase alfa Drugs 0.000 claims 1
- 108010072309 taliglucerase alfa Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960001032 trihexyphenidyl Drugs 0.000 claims 1
- 229960004406 velaglucerase alfa Drugs 0.000 claims 1
- -1 velaglucerase alfa Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057265P | 2020-07-27 | 2020-07-27 | |
| US63/057,265 | 2020-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202221125A true TW202221125A (zh) | 2022-06-01 |
Family
ID=77338944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110127422A TW202221125A (zh) | 2020-07-27 | 2021-07-26 | 用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230227802A1 (https=) |
| EP (1) | EP4189095A1 (https=) |
| JP (1) | JP2023536091A (https=) |
| KR (1) | KR20230093241A (https=) |
| CN (1) | CN117120619A (https=) |
| AU (1) | AU2021315876A1 (https=) |
| BR (1) | BR112023001456A2 (https=) |
| CA (1) | CA3190309A1 (https=) |
| IL (1) | IL299928A (https=) |
| MX (1) | MX2023000815A (https=) |
| TW (1) | TW202221125A (https=) |
| WO (1) | WO2022026409A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023215851A2 (en) * | 2022-05-06 | 2023-11-09 | Apic Bio, Inc. | Plasmid optimized for packaging of aav vectors |
| AU2023427408A1 (en) * | 2023-02-02 | 2025-09-04 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024226761A2 (en) * | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2024226790A1 (en) * | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2025039622A1 (zh) * | 2023-08-23 | 2025-02-27 | 上海金珂博生物技术有限公司 | 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途 |
| CN117264912A (zh) * | 2023-09-25 | 2023-12-22 | 中国科学院深圳先进技术研究院 | 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用 |
| CN118064436B (zh) * | 2024-04-18 | 2024-07-26 | 上海凌医生物科技有限公司 | 一种增强基因表达的嵌合启动子 |
| CN121518479B (zh) * | 2026-01-16 | 2026-04-24 | 凌意(杭州)生物科技有限公司 | 基因编辑复合型突变小鼠模型的构建方法 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5387484A (en) | 1992-07-07 | 1995-02-07 | International Business Machines Corporation | Two-sided mask for patterning of materials with electromagnetic radiation |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
| US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
| US5846528A (en) | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
| AU722375B2 (en) | 1996-09-06 | 2000-08-03 | Trustees Of The University Of Pennsylvania, The | Methods using cre-lox for production of recombinant adeno-associated viruses |
| WO1998011244A2 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Aav4 vector and uses thereof |
| JP2001506133A (ja) | 1996-12-18 | 2001-05-15 | ターゲティッド ジェネティクス コーポレイション | 組換えａａｖベクターの産生における使用のための、ａａｖスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株 |
| NZ333334A (en) | 1997-04-17 | 2001-06-29 | Frank L Sorgi | Delivery system for gene therapy to the brain |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP1124976A1 (en) | 1998-10-27 | 2001-08-22 | Crucell Holland B.V. | Improved aav vector production |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US6225113B1 (en) | 1998-12-04 | 2001-05-01 | Genvec, Inc. | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| JP2003523320A (ja) | 1999-09-29 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途 |
| US6365394B1 (en) | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| CA2409674C (en) | 2000-05-23 | 2010-05-11 | Neurologix, Inc. | Glutamic acid decarboxylase (gad) based delivery systems |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| WO2001096587A2 (en) | 2000-06-13 | 2001-12-20 | The Children's Hospital Of Philadelphia | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
| DE60129229T2 (de) | 2000-08-17 | 2008-05-08 | Ozawa, Keiya | Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren |
| US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| DK2573170T3 (en) | 2001-12-17 | 2018-04-09 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use |
| EP1463530A4 (en) | 2001-12-19 | 2006-09-06 | Lijun Wang | ADENO-ASSOCIATED VIRUS-RELATED DELIVERY OF GDNF TO SKELETAL MUSCLES |
| US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US8927269B2 (en) | 2003-05-19 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Avian adenoassociated virus and uses thereof |
| JP4888876B2 (ja) | 2003-06-13 | 2012-02-29 | 田平 武 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
| SI1633772T1 (sl) | 2003-06-19 | 2016-06-30 | Genzyme Corporation | AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US8137960B2 (en) | 2003-12-04 | 2012-03-20 | The United States Of America As Represented By The Department Of Health And Human Services | Bovine adeno-associated viral (BAAV) vector and uses thereof |
| US20060166363A1 (en) | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| EP1857552A1 (en) | 2006-05-20 | 2007-11-21 | Cargill Incorporated | Thermostable xylose isomerase enzyme |
| EP2311966A3 (en) | 2005-10-20 | 2012-09-05 | Amsterdam Molecular Therapeutics (AMT) B.V. | Improved AAV vectors produced in insect cells |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| CN103849629B (zh) | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
| EP2079840A4 (en) | 2006-10-30 | 2010-06-30 | Viventia Biotech Inc | IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| DK2173888T3 (en) | 2007-07-26 | 2016-11-28 | Uniqure Ip Bv | Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US9163261B2 (en) | 2010-02-22 | 2015-10-20 | Koteswara Rao KOLLIPARA | Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| CN103476399A (zh) | 2011-04-18 | 2013-12-25 | 独立行政法人国立精神·神经医疗研究中心 | 药剂递送粒子及其制造方法 |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| US20140359799A1 (en) | 2011-12-23 | 2014-12-04 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
| CN104411338A (zh) * | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| EP2900686B1 (en) | 2012-09-28 | 2020-06-10 | The University of North Carolina At Chapel Hill | Aav vectors targeted to oligodendrocytes |
| US9567376B2 (en) | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| ES2926774T3 (es) | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| MX380973B (es) | 2013-05-01 | 2025-03-12 | Genzyme Corp | Composiciones y metodos para tratar la atrofia muscular espinal. |
| EP3003391B1 (en) | 2013-05-31 | 2021-09-22 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| WO2015048534A1 (en) | 2013-09-26 | 2015-04-02 | University Of Florida Research Foundation, Inc. | Synthetic combinatorial aav capsid library for targeted gene therapy |
| US10087224B2 (en) | 2013-11-01 | 2018-10-02 | Cornell University | Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| AU2015320694B2 (en) | 2014-09-24 | 2021-11-11 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| AU2016219789B2 (en) | 2015-02-20 | 2021-03-25 | Fondazione Telethon | Methods and compositions for treating genetic eye diseases |
| WO2017015102A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for achieving high levels of transduction in human liver cells |
| ES2865487T3 (es) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores virales que evaden los anticuerpos |
| WO2017066764A2 (en) | 2015-10-16 | 2017-04-20 | William Marsh Rice University | Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses |
| WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| US10240145B2 (en) | 2015-11-25 | 2019-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer |
| KR102423442B1 (ko) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| BR112020006661A2 (pt) * | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| AU2018346104B2 (en) | 2017-10-03 | 2023-07-27 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| WO2019136484A1 (en) | 2018-01-08 | 2019-07-11 | Prevail Therapeutics, Inc. | Pet imaging ligands for in vivo detection of gba1 |
| JP2021517168A (ja) * | 2018-03-09 | 2021-07-15 | アブロバイオ，インコーポレーテッド | パーキンソン病を処置するための組成物及び方法 |
| BR112020021962A2 (pt) | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
| US20210214749A1 (en) * | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
| WO2020132455A1 (en) | 2018-12-21 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
-
2021
- 2021-07-26 BR BR112023001456A patent/BR112023001456A2/pt unknown
- 2021-07-26 EP EP21755300.7A patent/EP4189095A1/en active Pending
- 2021-07-26 MX MX2023000815A patent/MX2023000815A/es unknown
- 2021-07-26 AU AU2021315876A patent/AU2021315876A1/en active Pending
- 2021-07-26 JP JP2023505751A patent/JP2023536091A/ja active Pending
- 2021-07-26 CN CN202180066205.8A patent/CN117120619A/zh active Pending
- 2021-07-26 KR KR1020237006825A patent/KR20230093241A/ko active Pending
- 2021-07-26 US US18/018,017 patent/US20230227802A1/en active Pending
- 2021-07-26 WO PCT/US2021/043216 patent/WO2022026409A1/en not_active Ceased
- 2021-07-26 TW TW110127422A patent/TW202221125A/zh unknown
- 2021-07-26 IL IL299928A patent/IL299928A/en unknown
- 2021-07-26 CA CA3190309A patent/CA3190309A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230093241A (ko) | 2023-06-27 |
| US20230227802A1 (en) | 2023-07-20 |
| CA3190309A1 (en) | 2022-02-03 |
| JP2023536091A (ja) | 2023-08-23 |
| WO2022026409A1 (en) | 2022-02-03 |
| BR112023001456A2 (pt) | 2023-04-11 |
| EP4189095A1 (en) | 2023-06-07 |
| MX2023000815A (es) | 2023-04-11 |
| IL299928A (en) | 2023-03-01 |
| AU2021315876A1 (en) | 2023-02-23 |
| CN117120619A (zh) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI900553B (zh) | Aav蛋白殼之趨性重定向 | |
| AU2019346655B2 (en) | Frataxin expression constructs having engineered promoters and methods of use thereof | |
| AU2018260998B2 (en) | Modulatory polynucleotides | |
| AU2018261790B2 (en) | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) | |
| KR102850887B1 (ko) | Aav의 전달을 위한 조성물 및 방법 | |
| AU2018284960B2 (en) | AADC polynucleotides for the treatment of Parkinson's disease | |
| AU2024278250A1 (en) | Compositions and methods of treating Huntington's Disease | |
| TW202221125A (zh) | 用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法 | |
| RU2758488C2 (ru) | Модулирующие полинуклеотиды | |
| RU2764587C2 (ru) | Способы и композиции для лечения хореи гентингтона | |
| KR102907773B1 (ko) | 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법 | |
| AU2017315679B2 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| KR102606174B1 (ko) | 트리플 가이드 서열을 지닌 crispr/cas9를 사용한 엑손 스키핑 변형을 위한 최적화된 전략 | |
| KR20210019996A (ko) | 파킨슨병의 치료를 위한 조성물 및 방법 | |
| KR20230053735A (ko) | 게놈의 조정을 위한 개선된 방법 및 조성물 | |
| AU2020319168B2 (en) | Regulatable expression systems | |
| KR20220157944A (ko) | 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법 | |
| AU2019376084A1 (en) | Compositions and methods of inducing differentiation of a hair cell | |
| KR20230069157A (ko) | GJB2를 코딩하는 재조합 아데노 연관 바이러스 (rAAV) 및 그의 용도 | |
| CN112639108A (zh) | 治疗非综合征性感觉神经性听力损失的方法 | |
| KR20230146525A (ko) | 질환 치료 및 핵산 전달 개선 | |
| RU2836325C1 (ru) | Перенаправление тропизма капсидов aav | |
| TW202426651A (zh) | 具有工程化之啟動子之共濟蛋白(frataxin)表現構築體及其使用方法 | |
| CN116997657A (zh) | 编码GJB2的重组腺相关病毒(rAAV)及其用途 | |
| TWI923418B (zh) | 用於治療人類個體之非年齡相關性聽力障礙的組成物及方法 |